Belzutifan plus cabozantinib as first-line treatment for patients with advanced clear-cell renal cell carcinoma (LITESPARK-003): an open-label, single-arm, phase 2 study
2025; Elsevier BV; Volume: 26; Issue: 1 Linguagem: Inglês
10.1016/s1470-2045(24)00649-1
ISSN1474-5488
AutoresToni K. Choueiri, Jaime R. Merchan, Robert A. Figlin, David F. McDermott, Edward Arrowsmith, M. Dror Michaelson, Scott S. Tykodi, Elisabeth I. Heath, David R. Spigel, Anishka D'souza, Laurent Kassalow, Rodolfo F. Perini, Donna Vickery, Todd M. Bauer,
Tópico(s)Cancer Genomics and Diagnostics
Referência(s)